Periodic Reporting for period 2 - BIOS (BIOS: The bio-intelligent DBTL cycle, a key enabler catalysing the industrial transformation towards sustainable biomanufacturing)
Reporting period: 2024-04-01 to 2025-09-30
To access the products of interest via bioprocesses, typically multiple heterologous genes must be implemented into microbial production hosts. Whereas synthetic biology provides a multitude of novel tools for strain engineering, their rapid and effective implementation in microbial chassis for optimal performance under industrial conditions is still very challenging.
The bio-intelligent approach in BIOS aims to accelerate and improve the conventional ‘design-build-test-learn’ (DBTL) cycle for integrated strain and bioprocess engineering underpinning. Novel innovative metrics, biosensors and bioactuators are developed and fully integrated in the automation platform. Digital twins are created mimicking cellular and process levels. By tightly intertwining AI, not only the prediction quality is improved but, crucially, hybrid learning is made possible. The power of biDBTL will be showcased by creating P. putida producer strains for terpenes, renewable-based polyesters, and methylacrylate.
Experimentally, BIOS has established an integrated platform for building and testing strains. This includes a modern genome engineering toolkit (CRISPR-based control, efficient DNA insertion and recombineering), high-throughput electroporation hardware for rapid transformation in microtiter plates, and optimised cell-free protein synthesis protocols for fast part screening. In parallel, robust fluorescent reporter systems and automated RNA-sequencing workflows have been implemented to quantify gene expression and stress responses in a systematic, reproducible way and to feed these data directly back into the design–build–test–learn cycle.
These capabilities have already led to concrete biological and process advances. BIOS has identified the main stress factors that limit terpene and C1-based production in P. putida and uncovered hidden loss of production capacity over time in lycopene strains, guiding new engineering strategies. For methacrylate esters and other target molecules, new process concepts such as in situ product removal have delivered large increases in titres and much simpler downstream processing. Finally, life-cycle and techno-economic assessments are being used to benchmark these new routes against conventional production, ensuring that the technical innovations are aligned with environmental performance and future industrial viability.
Experimentally, BIOS has established an integrated genome-engineering and screening platform for P. putida, including CRISPR-based control, efficient DNA insertion methods and automated liquid-handling. A key technical outcome is the iPROBE high-throughput electroporation device for parallel transformation in microtiter plates with induction-based inline sterilisation, for which a patent application has been filed. Together with fluorescent reporters and automated RNA-seq, this allows high-quality data on stress and gene expression to feed directly into the design–build–test–learn cycle.
Scientifically, the project has identified oxidative and membrane stress as major limits for C1 and terpene production and shown that P. putida can consume isoprenol and lycopene, informing pathway design. For methacrylate esters, an in situ product removal concept achieved around 20-fold higher titres and nearly complete product export. Life-cycle and techno-economic analyses highlight solvents and energy use as main impact drivers and guide the Safe- and Sustainable-by-Design development of these new processes.